Hemo Organic Limited Submits Quarterly Compliance Certificate for Q4FY26

1 min read     Updated on 09 Apr 2026, 11:13 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Hemo Organic Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4FY26, confirming proper dematerialization processes. MCS Share Transfer Agent Limited issued the certificate on 8th April, 2026, validating that all securities were properly processed, certificates were mutilated after verification, and depository names were updated in member registers within 15 days. The submission demonstrates the company's adherence to regulatory requirements for the quarter ended 31st March, 2026.

powered bylight_fuzz_icon
37302219

*this image is generated using AI for illustrative purposes only.

Hemo organic Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026.

Regulatory Compliance Submission

The company submitted the compliance certificate on 9th April, 2026, in accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate was issued by MCS Share Transfer Agent Limited, the company's registrar and share transfer agent, dated 8th April, 2026.

Parameter: Details
Quarter Period: 31st March, 2026
Certificate Date: 8th April, 2026
Submission Date: 9th April, 2026
Registrar: MCS Share Transfer Agent Limited

Certificate Confirmation Details

MCS Share Transfer Agent Limited confirmed several key compliance aspects in their certificate. The registrar verified that all securities received from depository participants for dematerialization during the quarter were properly confirmed to the depositories. Additionally, they ensured that securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are already listed.

The certificate also confirms that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant. Importantly, the names of the depositories were substituted in the register of members as registered owners within the mandatory 15-day period.

Company and Registrar Information

Hemo Organic Limited, incorporated under CIN L24231GJ1992PLC018224, is headquartered in Ahmedabad, Gujarat. The company's managing director, Vishwambar Kameshwar Singh (DIN: 09822587), signed the submission letter digitally on 9th April, 2026.

MCS Share Transfer Agent Limited, operating under CIN U67120WD2011PLC165872, serves as the company's registrar and share transfer agent. The Ahmedabad-based registrar is located at Shatdal Complex on Ashram Road and was represented by their authorized signatory in issuing the compliance certificate.

Regulatory Significance

This quarterly submission represents standard regulatory compliance for listed companies, ensuring transparency in dematerialization processes and maintaining accurate shareholder records. The certificate validates that the company and its registrar have adhered to SEBI's prescribed timelines and procedures for handling securities dematerialization during the quarter ended 31st March, 2026.

Historical Stock Returns for Hemo Organic

1 Day5 Days1 Month6 Months1 Year5 Years
+4.97%+2.74%-9.29%+38.17%+16.20%-19.14%

Will Hemo Organic Limited's consistent regulatory compliance improve its ESG ratings and attract institutional investors?

How might SEBI's evolving digitalization initiatives impact the dematerialization process requirements for companies like Hemo Organic in upcoming quarters?

Could MCS Share Transfer Agent Limited's efficient compliance handling lead to expanded client relationships with other listed companies?

Hemo Organic Limited Announces Independent Director Resignation Under Regulation 30

2 min read     Updated on 01 Apr 2026, 12:06 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Hemo Organic Limited has formally notified BSE Limited about the resignation of Independent Director Mr. Deepak Ashokkumar Rochani (DIN: 11041560), effective from March 31, 2026. The resignation was attributed to pre-occupation and other professional commitments, with comprehensive regulatory documentation provided under SEBI Regulation 30.

powered bylight_fuzz_icon
36526812

*this image is generated using AI for illustrative purposes only.

Hemo Organic Limited has formally announced the resignation of Independent Director Mr. Deepak Ashokkumar Rochani, effective from the closure of business hours on March 31, 2026. The company submitted the required intimation to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Resignation Details

Mr. Deepak Ashokkumar Rochani (DIN: 11041560) submitted his resignation from the position of Independent Director due to pre-occupation and other professional commitments. The resignation was processed on March 31, 2026, with Managing Director Vishwambar Kameshwar Singh (DIN: 09822587) signing the official communication to BSE Limited.

Parameter: Details
Director Name: Mr. Deepak Ashokkumar Rochani
DIN: 11041560
Position: Independent Director
Effective Date: March 31, 2026
Reason: Pre-occupation and professional commitments
Board Committees: 3

In his resignation letter, Mr. Rochani confirmed that there are no other material reasons for his departure beyond those mentioned. He expressed gratitude to the Board of Directors and colleagues for their support during his tenure.

Regulatory Compliance and Documentation

The company provided comprehensive documentation as required under SEBI regulations, including the complete resignation letter and detailed annexure. The filing was made pursuant to Regulation 30 read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Compliance Aspect: Details
Regulation: SEBI Regulation 30
Scrip Code: 524590
Scrip Symbol: HEMORGANIC
ISIN: INE422G01015
Filing Date: March 31, 2026

Committee Impact and Reconstitution

Following Mr. Rochani's resignation, he stepped down from all board committees where he served as Chairman or Member. The company had previously reconstituted all three board committees with effect from April 1, 2026, ensuring continuity in governance structure.

Current Committee Structure

Committee: Chairman Members
Audit Committee: Ms. Rina Kumari Ms. Hiral Vinodbhai Patel, Mr. Vishwambar Kameshwar Singh
Nomination and Remuneration: Ms. Rina Kumari Ms. Hiral Vinodbhai Patel, Mr. Vishwambar Kameshwar Singh
Stakeholders Grievance: Ms. Rina Kumari Ms. Hiral Vinodbhai Patel, Mr. Vishwambar Kameshwar Singh

The reconstituted committees maintain consistent membership across all three committees, with Ms. Rina Kumari serving as Chairman and the same composition of members ensuring streamlined governance operations.

Historical Stock Returns for Hemo Organic

1 Day5 Days1 Month6 Months1 Year5 Years
+4.97%+2.74%-9.29%+38.17%+16.20%-19.14%

Will Hemo Organic recruit a new independent director to maintain board diversity and independence ratios?

How might the concentration of committee leadership under Ms. Rina Kumari affect governance oversight and decision-making processes?

Could this resignation signal broader governance challenges or strategic shifts within Hemo Organic's management structure?

More News on Hemo Organic

1 Year Returns:+16.20%